---
title: "OKYO Pharma Limited (OKYO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/OKYO.US.md"
symbol: "OKYO.US"
name: "OKYO Pharma Limited"
industry: "Biotechnology"
---

# OKYO Pharma Limited (OKYO.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [okyopharma.com](https://okyopharma.com) |

## Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye dise...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -19.49 | 511/605 | - | - | - |
| PB | -26.32 | 549/605 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-10T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.75 |
| Highest Target | 13.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/OKYO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/OKYO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/OKYO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.